Graph AI, a fast-growing life sciences technology startup specializing in pharmacovigilance and drug safety automation, has raised $3 million in seed funding led by Bessemer Venture Partners. The funding will accelerate the company’s mission to modernize patient safety and drug monitoring through AI-powered automation.
The company plans to use the fresh capital to expand its engineering team, speed up product development, and scale enterprise adoption globally.
Founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI operates within the rapidly growing $8 billion pharmacovigilance market—a crucial process where pharmaceutical companies track, analyze, and report adverse drug events (ADEs) to ensure ongoing patient safety.
Automating Drug Safety with AI
Traditionally, pharmacovigilance teams have depended on manual data collection from fragmented and unstructured sources such as medical reports, call transcripts, legal documents, and clinical literature. Graph AI’s flagship platform, Graph Safety, leverages artificial intelligence (AI) and intelligent automation to streamline these complex workflows.
The platform automates ADE case processing, signal detection, aggregate reporting, and regulatory compliance, significantly reducing human effort while maintaining audit-readiness and accuracy in medical review. Enterprise clients have reported faster compliance cycles, improved efficiency, and enhanced data accuracy using the system.
Scaling Global Operations
The Graph AI team brings together experts with prior experience at Infosys, LTI Mindtree, ServiceNow, Google, and Cisco, reflecting its strong blend of tech and life sciences expertise.
As it scales, the company aims to build on its early momentum across a pipeline of more than 7,000 marketed drugs, partnering with global pharmaceutical and biotech companies to drive the next wave of AI-driven pharmacovigilance transformation.
Driving the Future of Patient Safety
With AI and data intelligence transforming every corner of healthcare, Graph AI’s mission is to make drug safety faster, smarter, and more transparent. The funding marks a significant milestone for the company as it continues to position itself as a pioneer in pharmacovigilance technology.
By: Arushi Agarwal
